Navigation Links
Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy

in all treatment groups. No clinically significant changes in glucose or lipids were seen with nebivolol monotherapy during the study. -- "Addition of the Beta-Blocker Nebivolol to Ongoing Therapy in the Management of Mild-to-Moderate Hypertension" by Alan H. Gradman, MD, Chief, Division of Cardiovascular Diseases, The Western Pennsylvania Hospital. [Poster Presentation, P-383: Monday, May 21 from 12 pm to 1 pm (Riverside Hall)] The blood pressure lowering effects and tolerability of nebivolol added to ongoing antihypertensive therapy in patients was evaluated in this 12-week, randomized, double-blind, placebo-controlled study (n=669). Results indicate that, by comparison to placebo, nebivolol incrementally lowers blood pressure in mild to moderate hypertensive patients when added to ongoing antihypertensive therapy consisting of one or two medications from the following classes: ACE inhibitors, ARBs, or diuretics, with an incidence of reported adverse events similar to placebo. -- "Efficacy of the Novel Beta-blocker Nebivolol in Obese and Non-Obese Hypertensive Patients" by James R. Sowers, MD, Professor of Medicine and Physiology, Director Diabetes and Cardiovascular Center, University of Missouri. [Poster Presentation, P-442: Monday, May 21 from 12 pm to 1 pm (Riverside Hall)] The blood pressure lowering effects of nebivolol was compared in non- obese and obese hypertensive patients, a population that typically has a poorer response to treatment and an increased need for multiple medications. The pooled analysis of three randomized, double-blind, placebo-controlled trials of similar design was stratified by patient obesity status (BMI greater than or equal to 30 kg/m2) at baseline (obese, n=878; non-obese, n=1136). Results suggest that once-
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:7/30/2014)... , July 30, 2014  El Camino Hospital, a ... care, is utilizing the Leaf Patient Monitoring system to ... and movement of patients susceptible to bed sores. ... month-long, 138-patient study of the system, which showed dramatic ... Turning patients regularly is the one of the most ...
(Date:7/30/2014)... July 30, 2014  InnoPharma, Inc. today announced the ... generic equivalent of Zyprexa® injection), in Canada.  Olanzapine is ... behaviors in patients with schizophrenia or bipolar I mania. ... drug, InnoPharma has entered into an agreement with Sandoz ... will make, use, sell, market and distribute Olanzapine Injection ...
(Date:7/30/2014)... 30, 2014 Cynosure, Inc. (NASDAQ: ... treatments for non-invasive and minimally invasive applications, today announced that ... Operating Officer and Chief Financial Officer Timothy W. Baker ... Baker, 53, will continue to serve as CFO and will ... who remains Chairman and Chief Executive Officer. ...
Breaking Medicine Technology:El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2
(Date:7/30/2014)... revitalized and expanded through a U.S.-funded effort that ... access and providing cutting-edge skills labs and other ... by participants of the $130 million Medical Education ... progress being made at the African institutions. Their ... by the journal Academic Medicine . Begun ...
(Date:7/30/2014)... HealthDay Reporter WEDNESDAY, July 30, 2014 ... least 2,000 Americans die from extreme heat or cold, floods ... stroke or sun stroke caused nearly one-third of more than ... the U.S. Centers for Disease Control and Prevention. Cold ... -- accounted for 63 percent of those weather-related deaths. The ...
(Date:7/30/2014)... SF Cable, distributor of the highest quality cables, ... internet with guaranteed customer satisfaction announces the availability of ... These lightning cords are MFI certified to meet Apple ... Cable Lightning to USB Cables feature the ... and syncing. Compatible with the iPhone 5S/5C/5 plus iPad ...
(Date:7/30/2014)... 30, 2014 Visitors to our region ... $8,500 to ensure its protection. Bob Kiesendahl, one of ... to the Delaware Highlands Conservancy for donations collected through ... $2-per-stay donations add up fast, as visitors welcome the ... Delaware River Region. , The Kiesendahl family has owned ...
(Date:7/30/2014)... DRE Medical — a leading medical equipment ... its Medical Trade Shows & Conventions Calendar Schedule ... equipment vendors. , The calendar is a continually-updating guide ... States and around the world. Hundreds of entries are ... always growing. , Information listed on each trade show ...
Breaking Medicine News(10 mins):Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 3Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2
... Ensign Group, Inc. (Nasdaq: ENSG ), the parent company of the Ensign™ ... that its Board of Directors has declared a quarterly cash dividend of ... April 30, 2010 to shareholders of record as of March 31, ... ...
... March 15 Centocor Ortho Biotech Products has informed PharmaMar SA (Grupo Zeltia, ... have approved Yondelis(R) for advanced soft tissue sarcoma (STS) in adults. Furthermore, the authorities ... ovarian cancer (ROC). Yondelis is already approved for STS in Paraguay and ... ...
... Spotlighting the importance of oral health care for expectant mothers, the California Dental Association (CDA) Foundation has released new guidelines designed to emphasize the safety of dental treatment during ... ... ... ...
... at the University of Minnesota Medical School have discovered ... the hearts of Duchenne muscular dystrophy patients a ... children. The chemical, which Medical School scientists have termed ... heart muscle. When injected into the bloodstream, the molecular ...
... aspects of March Madness, offer tips to temper drawbacks , ... , , ... ... CHICAGO , March 15 ...
... ON , March 15 /PRNewswire-FirstCall/ - Nuvo Research ... the research and development of drug products that are delivered ... drug delivery technologies, and on the development of its immune ... the first patient in its European Phase 2 clinical trial ...
Cached Medicine News:Health News:The Ensign Group Declares Quarterly Dividend 2Health News:Yondelis(R) Receives Five New Approvals Outside the European Economic Area 2Health News:Yondelis(R) Receives Five New Approvals Outside the European Economic Area 3Health News:Yondelis(R) Receives Five New Approvals Outside the European Economic Area 4Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 2Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 3Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 4Health News:Researchers discover chemical that may protect hearts of muscular dystrophy patients 2Health News:Experts Say It's Not So Bad to Go a Little Mad 2Health News:Experts Say It's Not So Bad to Go a Little Mad 3Health News:Experts Say It's Not So Bad to Go a Little Mad 4Health News:Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial 2Health News:Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial 3Health News:Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial 4Health News:Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial 5
Lyphochek Coagulation Control is a human plasma control for monitoring the performance of routine coagulation tests. It has an extended reconstituted stability which helps reduce waste and save money...
Lyphochek® Hemoglobin A1C Linearity Set is a human whole blood based product designed to verify linearity throughout the patient reportable range of hemoglobin A1C assays....
... Hematology-16 Control is specifically ... most hematology analyzers that ... parameters and 3-part white ... trilevel control can be ...
Each Liquichek Seroconversion Panel features a series of serum specimens drawn over time from one individual to show the progression from a negative to a positive disease state....
Medicine Products: